On March 30, 2016, the kick-off meeting of the CAR-T clinical research project co-operated by the Affiliated Hospital of Xuzhou Medical College and Shanghai Longyao Biotechnology Co., Ltd. was held in the Affiliated Hospital of Xuzhou Medical College. Xu Kailin, Dean of the Affiliated Hospital of Xuzhou Medical College, Zheng Junnian, Vice President, Dr. Cao Jiang, Deputy Director of the Scientific Research Office, experts from the Hospital Cancer Institute, Hospital Hematology Department, and Oncology Department, Chairman Ye Shengqin and Vice President Li Wei of Shanghai Longyao Biotechnology Co., Ltd. , Vice President Wang Xin attended the meeting.
The Hematology and Oncology Center of the Affiliated Hospital of Xuzhou Medical University is a key medical discipline and a key clinical specialty in Jiangsu Province. It has undertaken the construction of multiple platforms of the Jiangsu Provincial Department of Science and Technology, the Health and Family Planning Commission, and the National Development and Reform Commission, and is well-known both inside and outside the province. In addition, Xu Medical Affiliated Hospital is the first international institution that has obtained the American AABB certification for the collection, preparation and clinical application of tumor immune cells. It has reached the international leading level in the standardized preparation, quality control and management of tumor immune cells.
Longyao Bio focuses on the research and transformation of tumor immune cell technology, and currently has a number of tumor targeted therapy technologies and products, such as DC1s-CTL technology, CAR-T technology, etc. In the field of CART technology, it has patented and proprietary technologies in the fields of virus transfection, memory CARTcm, and large-scale expansion of CART cells. It has achieved good experimental results in preclinical studies such as in vitro and humanized mouse models.
The meeting was presided over by Zheng Junnian, Vice President of Xuzhou Medical University. Dean Xu Kailin pointed out in his speech that the strong alliance between Longyao Biology and Xu Medical Affiliated Hospital hopes that through the close cooperation between the two parties, in the field of tumor immune cell technology, especially the technological innovation of CART , clinical innovation research and other aspects to create more international leading results. Ye Shengqin, chairman of Longyao Biotechnology, also made an enthusiastic speech, hoping to establish a domestic and international brand of CART technology through cooperation between the two parties. At the meeting, under the verification of leaders and experts, President Xu Kailin and Chairman Ye Shengqin signed a CART technology clinical research cooperation agreement, laying a solid foundation for the cooperation between the two parties.
At the same time, Dr. Li Wei from Longyao Biology made a detailed report on the CART technical route, technical advantages and organization and implementation methods. Dr. Cao Jiang, a physician in the Department of Hematology and Deputy Director of the Scientific Research Department of the Affiliated Hospital of Xu Medical University, gave a detailed introduction to the patient selection criteria, treatment plan, efficacy evaluation and follow-up plans in the CAR-T clinical research program. Experts participating in the meeting had a lively and fruitful discussion on the technical plan and development route of the project.
